Clinical trial
Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715
NCT00365781 · Ionis Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00365781 |
|---|---|
| Title | Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715 |
| Official title | A Phase 1, Open-Label Examination of the Dermatologic Effects From Subcutaneous Administration of ISIS 113715, and Antisense Oligonucleotide Inhibitor of Protein Tyrosine Phosphatase 1B, in Healthy Volunteers |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | ISIS 113715 |
| Enrollment | 10 |
| Start date | Aug 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Aug 17, 2006 |
| Last update posted | Oct 17, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: